Skip to main content
Top
Published in: Rheumatology International 10/2006

01-08-2006 | Original Article

Analgesic and disease modifying effects of interferential current in psoriatic arthritis

Authors: U. A. Walker, M. Uhl, S. M. Weiner, K. Warnatz, A. Lange-Nolde, H. Dertinger, H. H. Peter, S. A. Jurenz

Published in: Rheumatology International | Issue 10/2006

Login to get access

Abstract

Interferential current (IFC) was suggested to improve the skin manifestations of psoriasis vulgaris, possibly by enhancing the intracellular concentration of cyclic AMP. We assessed the efficacy of IFC on psoriatic arthritis (PsA). Nine consecutive patients were analyzed at baseline and after 16 weeks of IFC therapy. Bipolar IFC was applied twice daily to hands, feet plus all affected joints. IFC improved SF-36 assessed body pain, but not other SF-36 subscales. Morning stiffness, tender joint counts, and physician assessed disease activity improved. In contrast, visual analogue scale assessed pain, CRP and ESR measurements were unchanged. MRI of the most affected hand or foot documented a tendency towards worsened tendinitis, soft tissue swelling, and new joint space narrowing and erosions. Bone scintigraphy showed a trend towards deterioration. New joints became inflamed within treated sites. Thus IFC has analgesic effects in PsA, but does not have a satisfactory disease modifying effect.
Literature
1.
go back to reference Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385–390PubMedCrossRef Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385–390PubMedCrossRef
2.
go back to reference Philipp A, Wolf GK, Rzany B, Dertinger H, Jung EG (2000) Interferential current is effective in palmar psoriaris: an open prospective trial. Eur J Dermatol 10:195–198PubMed Philipp A, Wolf GK, Rzany B, Dertinger H, Jung EG (2000) Interferential current is effective in palmar psoriaris: an open prospective trial. Eur J Dermatol 10:195–198PubMed
3.
go back to reference Sontag W (2000) Modulation of cytokine production by interferential current in differentiated HL-60 cells. Bioelectromagnetics 21:238–244PubMedCrossRef Sontag W (2000) Modulation of cytokine production by interferential current in differentiated HL-60 cells. Bioelectromagnetics 21:238–244PubMedCrossRef
4.
go back to reference Sontag W (2004) Response of cyclic AMP by DMSO differentiated HL-60 cells exposed to electric interferential current after prestimulation. Bioelectromagnetics 25:176–184PubMedCrossRef Sontag W (2004) Response of cyclic AMP by DMSO differentiated HL-60 cells exposed to electric interferential current after prestimulation. Bioelectromagnetics 25:176–184PubMedCrossRef
5.
go back to reference Royer E, Chaintreul J, Meynadier J, Michel B, Guilhou JJ, Crastes DP (1982) Cyclic AMP and cyclic GMP production in normal and psoriatic epidermis. Dermatologica 165:533–543PubMedCrossRef Royer E, Chaintreul J, Meynadier J, Michel B, Guilhou JJ, Crastes DP (1982) Cyclic AMP and cyclic GMP production in normal and psoriatic epidermis. Dermatologica 165:533–543PubMedCrossRef
6.
go back to reference Asadullah K, Sabat R, Friedrich M, Volk HD, Sterry W (2004) Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis. Curr Drug Targets Inflamm Allergy 3:185–192PubMedCrossRef Asadullah K, Sabat R, Friedrich M, Volk HD, Sterry W (2004) Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis. Curr Drug Targets Inflamm Allergy 3:185–192PubMedCrossRef
7.
go back to reference Platzer C, Meisel C, Vogt K, Platzer M, Volk HD (1995) Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int Immunol 7:517–523PubMedCrossRef Platzer C, Meisel C, Vogt K, Platzer M, Volk HD (1995) Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int Immunol 7:517–523PubMedCrossRef
8.
go back to reference Sontag W, Dertinger H (1998) Response of cytosolic calcium, cyclic AMP, and cyclic GMP in dimethylsulfoxide-differentiated HL-60 cells to modulated low frequency electric currents. Bioelectromagnetics 19:452–458PubMedCrossRef Sontag W, Dertinger H (1998) Response of cytosolic calcium, cyclic AMP, and cyclic GMP in dimethylsulfoxide-differentiated HL-60 cells to modulated low frequency electric currents. Bioelectromagnetics 19:452–458PubMedCrossRef
10.
go back to reference Wassenberg S, Fischer-Kahle V, Herborn G, Rau R (2001) A method to score radiographic change in psoriatic arthritis. Z Rheumatol 60:156–166PubMedCrossRef Wassenberg S, Fischer-Kahle V, Herborn G, Rau R (2001) A method to score radiographic change in psoriatic arthritis. Z Rheumatol 60:156–166PubMedCrossRef
11.
go back to reference Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML, Cush JJ, Schumacher HR Jr, Silverman SL, Alepa FP, Luggen ME, Cohen MR, Makkena R, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG (1996) Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39:2013–2020PubMedCrossRef Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML, Cush JJ, Schumacher HR Jr, Silverman SL, Alepa FP, Luggen ME, Cohen MR, Makkena R, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG (1996) Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39:2013–2020PubMedCrossRef
12.
go back to reference Cheing GL, Hui-Chan CW (2003) Analgesic effects of transcutaneous electrical nerve stimulation and interferential currents on heat pain in healthy subjects. J Rehabil Med 35:15–19PubMedCrossRef Cheing GL, Hui-Chan CW (2003) Analgesic effects of transcutaneous electrical nerve stimulation and interferential currents on heat pain in healthy subjects. J Rehabil Med 35:15–19PubMedCrossRef
13.
go back to reference Johnson MI, Tabasam G (2003) An investigation into the analgesic effects of different frequencies of the amplitude-modulated wave of interferential current therapy on cold-induced pain in normal subjects. Arch Phys Med Rehabil 84:1387–1394PubMedCrossRef Johnson MI, Tabasam G (2003) An investigation into the analgesic effects of different frequencies of the amplitude-modulated wave of interferential current therapy on cold-induced pain in normal subjects. Arch Phys Med Rehabil 84:1387–1394PubMedCrossRef
14.
go back to reference McInnes IB, Illei GG, Danning CL, Yarboro CH, Crane M, Kuroiwa T, Schlimgen R, Lee E, Foster B, Flemming D, Prussin C, Fleisher TA, Boumpas DT (2001) IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 167:4075–4082PubMed McInnes IB, Illei GG, Danning CL, Yarboro CH, Crane M, Kuroiwa T, Schlimgen R, Lee E, Foster B, Flemming D, Prussin C, Fleisher TA, Boumpas DT (2001) IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 167:4075–4082PubMed
Metadata
Title
Analgesic and disease modifying effects of interferential current in psoriatic arthritis
Authors
U. A. Walker
M. Uhl
S. M. Weiner
K. Warnatz
A. Lange-Nolde
H. Dertinger
H. H. Peter
S. A. Jurenz
Publication date
01-08-2006
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 10/2006
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-006-0102-y

Other articles of this Issue 10/2006

Rheumatology International 10/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine